Researchers in South Korea have uncovered a previously underappreciated molecular circuit that appears to help breast cancer turn the body’s own immune cells into quiet accomplices. The study, published in Cancer Immunology, Immunotherapy, identifies the growth factor FLT3 ligand, or FLT3LG, as a signal induced in CD4+ T cells by gamma-chain cytokines, and shows that when T cells produce FLT3LG they drift away from their tumor-killing duties and adopt features reminiscent of regulatory T cells, the immune system’s own brakes.
The findings come from a team led by Yeo-Jin Im, Hyeon-Ji Hwang, Chae-Yi Kim and senior author Je-Yoel Cho at Seoul National University, whose work was supported by the National Research Foundation of Korea. What makes the study compelling is the way it stitches together multiple lines of evidence, from bulk and single-cell transcriptomic data in human patients to controlled experiments in cell culture and a mouse model of mammary tumors, all pointing toward the same conclusion: FLT3LG is enriched in CD4+ T cells within breast tumors, and its expression is linked to immunosuppressive, Treg-like programs that correlate with worse clinical outcomes in particular breast cancer subtypes.
Breast cancer, like many solid tumors, does not simply outgrow the immune response. It actively reshapes it. Among the infiltrating immune cells in breast tumors are CD4+ T cells that have taken on regulatory or dysfunctional states, dampening antitumor immunity and contributing to what immunologists call immune evasion. But the molecular programs that drive otherwise ordinary helper T cells into these tumor-tolerant states have remained only partially mapped. The Seoul team set out to find factors that mark and possibly drive this transformation, and FLT3LG emerged as a striking candidate.
FLT3LG is best known in hematology as a cytokine that supports the development of dendritic cells and hematopoietic progenitors through its receptor, FLT3, and it has a complicated, sometimes contradictory reputation in cancer biology. The new study reframes it in a specific immunological context: as a factor produced by CD4+ T cells themselves in response to signals abundant in the tumor microenvironment.
Using publicly available transcriptomic datasets and single-cell RNA sequencing analyses, the researchers showed that FLT3LG expression in breast cancer was associated with gene signatures enriched for regulatory T cells and broader immune regulatory activity. In other words, tumors where CD4+ T cells expressed high levels of FLT3LG were also tumors where the immune landscape looked conspicuously tolerant, dominated by cells whose job is to suppress rather than attack.
To test whether FLT3LG is merely a passive marker or an active driver of this phenotype, the team turned to Jurkat cells, a widely used human T lymphocyte cell line. When they engineered Jurkat T cells to overexpress FLT3LG, the cells underwent a notable shift. Levels of regulatory markers and immune inhibitory receptors climbed, while the expression of effector cytokines, the inflammatory molecules T cells use to coordinate attacks on infected or malignant cells, dropped. The cells also showed reduced proliferative capacity. Importantly, the authors characterize this as a regulatory-like state with reduced effector function rather than full-blown, bona fide regulatory T cell differentiation. The distinction matters: FLT3LG appears to push CD4+ T cells toward a suppressive, exhausted-adjacent identity without making them canonical Tregs, suggesting a partial or intermediate reprogramming.
The team then asked what triggers FLT3LG production in the first place. Gamma-chain cytokines, a family of interleukins that includes IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21, signal through receptors sharing the common gamma chain and classically activate the transcription factor STAT5. In their experiments, the researchers demonstrated that gamma-chain cytokines induce FLT3LG expression in T cells through STAT5-dependent signaling. This provides a plausible mechanistic link to the tumor microenvironment, where such cytokines are often present at high levels and where STAT5 signaling in T cells can be co-opted by tumors to promote tolerance.
The interplay between breast cancer cells and T cells was examined directly in co-culture experiments. When Jurkat cells or primary human T cells were cultured alongside HER2-positive breast cancer cell lines, the tumor cells induced expression of both FLT3LG and FOXP3, the master transcription factor of regulatory T cells, in the T cells. This suggests that HER2-positive breast cancer cells actively push approaching T cells toward the regulatory program that FLT3LG marks and promotes.
The consequences for the tumor were measurable. In these co-culture systems, the presence of FLT3LG-overexpressing T cells was associated with increased Ki-67 expression in the breast cancer cells, a marker of proliferation, and with reduced apoptosis, meaning the cancer cells were dividing more and dying less. The researchers also observed altered CFSE profiles in primary responder T cells, indicating changes in the division behavior of conventional T cells exposed to this environment. Taken together, these results paint a picture in which FLT3LG-producing CD4+ T cells foster conditions favorable to tumor expansion while dampening the proliferative response of potentially tumor-reactive lymphocytes.
To confirm that these cellular dynamics play out in living tissue, the team used a syngeneic mammary tumor model in mice, in which tumors can be studied within an intact immune system. As tumors progressed, FLT3LG expression rose in CD4+ T cells, and the increase was particularly pronounced within the regulatory T cell subset itself. This longitudinal view strengthens the argument that FLT3LG induction is not an artifact of cell culture but accompanies genuine tumor-driven immune remodeling over time.
The clinical relevance emerged from analysis of human breast cancer datasets. High FLT3LG expression was associated with poor patient outcomes specifically in HER2-positive breast cancer and in highly proliferative tumor contexts. This subtype specificity is notable. HER2-positive tumors are already known for their inflammatory, immune-infiltrated character, and therapies targeting HER2, such as trastuzumab, partly work by engaging the immune system. If FLT3LG-driven regulatory programming in CD4+ T cells contributes to immune suppression in precisely these tumors, it could help explain why some patients respond robustly to immunotherapy-oriented approaches while others do not, and it may point to combination strategies that pair HER2-directed treatment with interventions targeting this newly described circuit.
The study’s conceptual contribution is the delineation of what the authors call a gamma-chain cytokine–STAT5–FLT3LG regulatory circuit. In this model, cytokines signaling through the common gamma chain activate STAT5 in CD4+ T cells, driving FLT3LG production, which in turn promotes regulatory-like features, elevated inhibitory receptors and reduced effector function, ultimately blunting antitumor immunity. Each node of this circuit is a potential intervention point. Blocking FLT3LG signaling, modulating specific gamma-chain cytokines, or targeting downstream STAT5 activity are all avenues that could, in principle, interrupt the pathway. The authors are careful to note that the work is at the mechanistic and preclinical stage; translating it into therapies will require determining whether FLT3LG is a practical drug target, what its receptor-mediated effects on other immune cells contribute in vivo, and whether its suppression would carry unacceptable costs to normal immune function, given FLT3LG’s established roles in dendritic cell development.
There is also a broader lesson in the study’s methodology. By triangulating between patient datasets, single-cell sequencing, cell-line overexpression systems, primary human T cells, co-culture models and a mouse tumor model, the researchers built a case in which each approach compensates for the limitations of the others. Transcriptomic correlations alone cannot establish causality, and cell-line experiments cannot fully capture the complexity of a living tumor. The convergence of evidence across these platforms is what lends the gamma-chain cytokine–STAT5–FLT3LG axis its credibility as a genuine feature of breast cancer immunobiology rather than a culture artifact.
For a field that has concentrated much of its immunotherapy energy on CD8+ cytotoxic T cells and checkpoint blockade, the study adds weight to the growing recognition that CD4+ T cells, particularly those sliding into regulatory-like states, are central arbiters of the antitumor response. If future work confirms FLT3LG’s role and druggability, monitoring or targeting this pathway could become part of the toolkit for treating HER2-positive and highly proliferative breast cancers, where the immune system’s brakes appear, at least in part, to be applied by a molecule few oncologists had previously watched this closely.
Subject of Research: The role of FLT3 ligand (FLT3LG), induced by gamma-chain cytokine–STAT5 signaling, in promoting regulatory-like CD4+ T cell features and immune evasion in breast cancer
Subject of Research: Cancer
Article Title: FLT3LG induction by γ-chain cytokine promotes regulatory-like CD4+ T cell features in breast cancer
Article References: Im, Y.-J., Hwang, H.-J., Kim, C.-Y., & Cho, J.-Y. (2026). FLT3LG induction by γ-chain cytokine promotes regulatory-like CD4+ T cell features in breast cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04492-y
Image Credits: AI Generated
DOI: 10.1007/s00262-026-04492-y
Keywords: FLT3LG, γc cytokine, STAT5, Treg, CD4+ T cells, breast cancer, immune evasion, T cell dysfunction, FOXP3, HER2-positive breast cancer, tumor microenvironment, immunoregulation
Cite Scienmag News
APA MLA Chicago
Nathaniel Bowman. (September 7, 2026). Gamma-chain cytokines drive FLT3LG, fostering regulatory-like CD4 T cells in breast cancer. Scienmag. https://scienmag.com/gamma-chain-cytokines-drive-flt3lg-fostering-regulatory-like-cd4-t-cells-in-breast-cancer/
Copy citation Download RIS
Tags: breast cancer immune evasionbreast cancer immunotherapy targetsbreast cancer subtypes and immune responsecytokine signaling in tumor immune modulationFLT3 ligand in tumor microenvironmentFLT3 ligand role in immune regulationgamma-chain cytokines in cancergamma-chain cytokines in tumor microenvironmentimmune cell plasticity in breast tumorsimmune suppression mechanisms in breast cancerimmunosuppressive T cell programs in breast cancerimpact of cytokine signaling on tumor immunityimpact of FLT3LG on T cell phenotypemolecular mechanisms of immune escape inmolecular pathways driving T cell regulatory functionsregulatory-like CD4 T cells in breast cancerregulatory-like CD4 T cells in breast tumorsrole of FLT3LG in immune regulationsingle-cell transcriptomics in cancer researchtumor microenvironment immune dynamicstumor-associated immune cell reprogrammingtumor-associated immunosuppression mechanisms
